Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 982
countries
28
conditions
2 109

9 trials match your criteria

Crigler-Najjar syndrome

Recruiting

Study of GNT0003 and imlifidase in adults with Crigler-Najjar syndrome who require daily phototherapy and have pre-existing AAV8 antibodies

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium

Kidney transplant rejection

Recruiting

Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imlifidase

Duchenne muscular dystrophy gene carrier

Not recruiting

Study on the Safety and Efficacy of Delandistrogene Moxeparvovec and Imlifidase for Patients with Duchenne Muscular Dystrophy with Pre-existing Antibodies

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Imlifidase

Neuromyelitis optica spectrum disorder

Not recruiting

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Kidney transplant rejection

Not recruiting

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Anti-glomerular basement membrane disease

Not recruiting

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Kidney transplant rejection

Not recruiting

Long-Term Follow-Up Study of Imlifidase in Highly Sensitized Kidney Transplant Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Acute respiratory distress syndrome+3

Not recruiting

Study on Imlifidase for Patients with Severe ANCA-Associated Vasculitis and Lung Bleeding

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Renal transplant

Not recruiting

Study of Imlifidase for Patients Undergoing Kidney Transplant from a Living Donor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Imlifidase

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.